OmniSpirant Therapeutics is a biotech developing a disruptive RNA delivery platform technology, ‘OmniSomes’ This proprietary technology is highly differentiated utilizing bioengineered Mesenchymal Stem Cell derived extracellular vesicles (EVs) as novel non-viral vectors for highly efficient RNA delivery which uniquely confer additional regenerative medicine properties and benefits.
OmniSpirant are taking a novel approach to tackling cancer with their lead program (OS003, a pan-cancer gene therapy) based on this technology. OS003's development has been funded since June 2022 via a €13.4M Horizon Europe grant award.
OmniSpirant also develops inhaled regenerative gene therapies for cystic fibrosis, acute respiratory distress syndrome, and other lung diseases, aiming to revolutionize treatment for millions of patients globally.
Why work with us
Mutations in TP53 are the most frequent genetic alterations in human cancers, where the mutated p53 protein contributes strongly to cancer progression and therapy resistance
Abnormalities in the p53 pathway are present in virtually all cancers, yet TP53/p53 is widely considered as 'undruggable'.
OmniSpirant addresses this through its innovative technology, OmniSomes, which uses stem cell EVs for the targeted and non-immunogenic delivery of tumor suppressor RNA payloads. Our TP53 based gene therapy, OS003 is designed to be a safer and more effective alternative to traditional cancer treatments by tapping into the body's natural RNA transport system. With promising results in preclinical models, we aim to reach clinical trials targeting TP53-mutated orphan cancers within 24 months with the potential for accelerated regulatory approval within 48 months.
Our versatile first-in-class regenerative gene therapy platform is capable of efficient intracellular RNA and protein delivery via inhaled and intravenous routes of administration. Partnered co-development with larger pharma partners can expand OmniSomes transformational potential for a wide variety of disease indications and turn OmniSpirant a highly profitable company while still at preclinical stages of development. The versatility of our differentiated platform extends to diverse therapeutic applications to solve difficult delivery problems (in vivo CAR-T or CARs for broader immune cell transformation, CNS targeted delivery to address major neurodegenerative diseases with regenerative targeted therapies, in vivo gene editing etc.).
